

## Limited Submission Announcement

A limited submission opportunity is available from the Cancer Prevention & Research Institute of Texas (CPRIT) and is available on the [UTSA Limited Submission Opportunities webpage](#).

### [CPRIT Early Translational Research Awards Program Overview](#)

CPRIT's Academic Research and Product Development Research programs have established 2 new RFA mechanisms aimed at the development of innovative technologies at Texas research institutions that demonstrate great promise to impact the cancer burden in Texas and elsewhere. The Early Translational Research Award (ETRA) described in this RFA and the companion Seed Funding Award mechanism by CPRIT's Product Development Research program are being offered to fund the development of therapeutics, devices, or diagnostic assays designed to lessen the burden of cancer. The aim of these awards is to narrow the funding gap (sometimes referred to as the "valley of death") for the preclinical development of oncology products and to address the need for involvement of business expertise early in the preclinical product development stages. The overall goal of these mechanisms is to create a pipeline of promising new cancer products developed by the Texas bioscience community and to advance successful technology commercialization and company development.

The ETRA is intended to bridge the gap between promising new discoveries achieved in the research laboratory and the commercial development of a therapeutic product, medical device, or diagnostic assay through activities up to and including preclinical proof-of-concept data that demonstrate applicability to the planned clinical scenario. The work funded under this RFA must be deemed sufficiently robust such that successful completion would result in a lead product that has compelling evidence of efficacy in qualified models, a favorable preliminary safety profile, and, for therapeutics, evidence of feasibility of scale-up and bulk synthesis. In other words, at the completion of the project it will be clear if the lead product under development has the attributes necessary to attract private investment to continue its development toward IND-enabling studies (IDE-enabling preclinical plan in the case of a medical device) and clinical evaluation.

### Eligibility

- The Principal Investigator (PI) must have a doctoral degree, including MD, PhD, DDS, DMD, DrPH, DO, DVM, or equivalent and must reside in Texas during the time the research that is the subject of the grant is conducted.
- A PI may submit only one (1) application under this RFA during this funding cycle. Only one (1) Co-PI may be included. The Co-PI must reside in Texas for the period of the time that the research that is the subject of the grant is conducted.

See RFA for complete list of eligibility criteria

### Application Limit

The institutional application limit for UTSA is one (1).

### Award Amount

Applicants may request up to \$2,000,000 in total costs over a period of 1 to 2 years.

## Limited Submission Announcement

### **Internal Evaluation Criteria**

The attached review matrix will be utilized for internal review/scoring. Pre-proposals should be responsive to these criteria.

### **Timeline**

Internal Notice of Intent Due (Preferred)	Limited Submission Application Due	Selection Notification	Application Due to Funder
September 17, 2018	September 24, 2018	October 9, 2018	January 30, 2019

### **[Limited Submission Application Instructions](#)**

### **[Limited Submission Application](#)**

Questions? Please reference the [UTSA Limited Submission website](#) or contact [LimitedSubmissions@utsa.edu](mailto:LimitedSubmissions@utsa.edu)